Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]